C
URGN icon

Covestor’s UroGen Pharma URGN Stock Holding History

Covestor’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Buy
14
+8
+133% +$217 ﹤0.01% 2369
2026
Q1 		$0 Buy
+6
New +$120 ﹤0.01% 2799
2025
Q4 		– Sell
-68
Closed -$1K – 2763
2025
Q3 		$1K Buy
+68
New +$1.22K ﹤0.01% 2197

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Covestor's URGN Position: Q2 2026 in Review

Covestor increased its UroGen Pharma (URGN) stake by 133% in Q2 2026, buying an estimated $217 and bringing the position to 14 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2369.

Covestor first reported a position in URGN in Q3 2025 and has held it in 3 quarters since. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Covestor held 14 shares of UroGen Pharma worth $1K as of Q2 2026.
  • Covestor bought 8 UroGen Pharma shares in Q2 2026, an estimated $217.
  • UroGen Pharma made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2369 holding.
  • Covestor first reported a position in UroGen Pharma in Q3 2025 and has held it in 3 quarters since.
  • 190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.